Joseph Payne, Arcturus CEO (Arcturus via YouTube)
November 2, 2022 09:12 AM EDTUpdated 09:34 AM
Deals

CSL stacks up $4.5B in chips — with a $200M ante — to wa­ger on the next-gen mR­NA wave

John Carroll

Editor & Founder

Aus­tralian phar­ma gi­ant CSL is mak­ing a late bid for mR­NA glo­ry, and they’ve lined up one of the al­so-ran US Covid-19 biotechs tout­ing their …

Endpoints News

Sign up to read this article for free.

Get free access to a limited number of articles, plus choose newsletters to get straight to your inbox.

BECOME A PREMIUM SUBSCRIBER
TRENDING NOW

The End­points 2024 win­ners and losers list: Who was up and who was down in bio­phar­ma

FDA ap­proves Hu­ma­cyte’s lab-grown blood ves­sels in mile­stone for re­gen­er­a­tive med­i­cine

Up­dat­ed: No­vo’s 23% weight loss with Ca­griSe­ma falls short of high ex­pec­ta­tions, new tri­al planned

Ac­cel­er­at­ed ap­proval brings Pfiz­er's BRAF in­hibitor to first-line pa­tients

Ex­clu­sive: Flori­da can­cer biotech rais­es $100M Se­ries A

Califf, on his way out at FDA, pre­dicts agency tug-of-war be­tween Ra­maswamy and RFK Jr.

A service from the Financial Times